Verona, Italy

Agostino Cianciulli

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Agostino Cianciulli: Innovator in Cancer and Metabolic Disorder Treatments

Introduction

Agostino Cianciulli is a notable inventor based in Verona, Italy. He has made significant contributions to the field of medicinal chemistry, particularly in the development of treatments for cancer and metabolic disorders. His innovative work has led to the discovery of novel compounds that hold promise for various therapeutic applications.

Latest Patents

Cianciulli holds a patent for "Small-molecule PI5P4K alpha/beta inhibitors and methods of treatment using same." This patent relates to the discovery of novel 2-amino-dihydropteridinone compounds and their analogues, which are capable of inhibiting phosphatidylinositol phosphate kinases. The compounds described in this patent can be utilized to treat p53-null cancer in subjects. Additionally, they may be effective in treating metabolic disorders, including type 2 diabetes and obesity.

Career Highlights

Agostino Cianciulli is affiliated with Yale University, where he continues to advance his research in the field of pharmacology. His work has garnered attention for its potential impact on treating serious health conditions. With one patent to his name, he is recognized for his innovative approach to drug development.

Collaborations

Cianciulli has collaborated with esteemed colleagues, including Ya Ha and Jonathan A Ellman. These partnerships have contributed to the advancement of his research and the development of new therapeutic strategies.

Conclusion

Agostino Cianciulli is a prominent figure in the realm of medicinal chemistry, with a focus on developing treatments for cancer and metabolic disorders. His innovative discoveries and collaborations highlight his commitment to advancing healthcare solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…